Law Articles
To search for a particular term please use the following search box.
Law Topics
Click on a Topic to see available articles for that topic.
- Accidents
- Administrative Law
- Admiralty Law
- Articles
- Banking
- Bankruptcy Law
- Canon Law
- Case Law
- Civil Law
- Civil Rights
- Class Action Lawsuits
- Commercial Law
- Common Law
- Comparative Law
- Constitutional Law
- Consumer Law
- Contracts
- Corporate Law
- Courts
- Criminal Law
- Cyber Law
- Dispute Resolution
- Employment Law
- Equity
- Evidence
- Family Law
- Fiduciary Law
- General Practice
- Government
- Health Law
- Immigration Law
- Insurance Law
- Intellectual Property
- International Law
- Jurisprudence
- Labor Law
- Law and Economics
- Maritime Law
- Military Law
- Natural Law
- Personal Injury Law
- Philosophy of Law
- Property Law
- Public Law
- Real Estate Law
- Social Security
- Space Law
- Statutory Law
- Tax Law
- Traffic Law
- Trusts and Estates
- Water Law
Return to Law Dictionary Index
Attorneys Request Bextra Lawsuits be Transferred to Louisiana
Source: PR Newswire
Published: April 08, 2005
Pfizer Inc., the world's largest drug maker, said Thursday it would remove the arthritis drug Bextra from the market. Following yesterday's announcement, Louisiana attorneys for Bextra and Celebrex patients asked today a judicial panel in Washington, D.C. to move all Bextra and Celebrex lawsuits in the country to one federal court, the U.S. District Court for the Eastern District of Louisiana, which is in New Orleans, for consolidation and management.
Bextra was taken off the market because the overall risk versus benefit profile for the drug is "unfavorable," the Food and Drug Administration said in a statement.
Concerns about the safety of COX-2 inhibitors, like Bextra and Celebrex, another drug made by Pfizer, increased when Vioxx was pulled from the market by Merck & Company in September 2004, after a study found that it increases a patients' risk of heart attack and stroke.
But unlike Vioxx, Bextra was taken off the market because of its potential to cause a rare but serious skin reaction, which is already disclosed on its label, Pfizer said.
Hundreds of Vioxx lawsuits, individual and class actions, were consolidated and transferred to the federal court in New Orleans before Judge Eldon E. Fallon.
"All of the cases involving Vioxx have been transferred to the federal court in New Orleans and it would be appropriate if the Bextra/Celebrex litigation were here also," Louisiana attorney Richard J. Arsenault said in a statement.
Pfizer has claimed that Bextra does not present the same heart-related risks as Vioxx. However, Dr. Garret FitzGerald, a cardiologist and pharmacologist at the University of Pennsylvania, presented the results of a study involving 12 clinical trials and 5,930 participants, at the American Heart Association's annual conference in November 2004, that found that people who took Bextra experienced twice the number of heart attacks and strokes compared with those given placebos.
Read Full Story at PR Newswire